Grifols reported EUR979.78M in Cash and Equivalent for its fiscal quarter ending in December of 2024.





Cash And Equivalent Change Date
Alaunos Therapeutics USD 124K 230K Jun/2026
Arca Biopharma USD 191.52M 76.95M Sep/2026
aTyr Pharma USD 13.14M 3.02M Sep/2026
Bio Path 13.65M 3.37M Sep/2022
Brainstorm Cell Therapeutics USD 22K 7K Jun/2026
Capricor Therapeutics USD 44.28M 23.34M Sep/2026
Cara Therapeutics USD 22.28M 2.42M Sep/2026
GlaxoSmithKline GBP 3.1B 337M Jun/2026
Grifols EUR 979.78M 334.84M Dec/2024
Immunic USD 131.96M 23.14M Sep/2026
Minerva Neurosciences USD 82.3M 70.02M Dec/2025
Nektar Therapeutics USD 149.58M 134.46M Mar/2026
Sangamo BioSciences USD 38.34M 13.16M Jun/2025
TherapeuticsMD 523K 89K Jun/2024